Maplight Therapeutics Inc (MPLT) Stock Price, Quote & News

Company Profile

MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spectrum disorder; ML-021 for the treatment of motor deficits in Parkinson's diseas...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 984 6300

Website: www.maplightrx.com

Address:

800 Chesapeake Drive, Redwood City, United States

prismmarketview Aug. 14 at 1:37 PM

$150 million is going behind the next stage of schizophrenia drug development. MapLight Therapeutics ($MPLT) raised $150M following positive Phase 2 results for ML-007C-MA, including a signal in cognition. Across the field, companies are targeting different gaps in schizophrenia care: longer-acting treatments at $TEVA, a newly approved option from $VNDA, and negative symptoms at $NERV. The pipeline is moving beyond controlling psychosis toward addressing more of the disease’s full burden. https:// prismmarketview.com/maplight-raise s-150-million-as-schizophrenia-drug-development-broadens/ $MPLT $TEVA $VNDA $NERV

0 · Reply

Biotech_Pharma_Investor Aug. 14 at 8:59 AM

$MPLT my summary assessment for anyone interested https://substack.com/profile/160232761-biotech-pharma-investor/note/c-314520519?r=2nece1

0 · Reply

QuantInsider Aug. 13 at 8:58 PM

$MPLT is taking a hit, down nearly 13% in the last five sessions Today’s little bounce doesn’t change the bearish vibe The options tape is showing heavy buying of long-dated, deep ITM puts About $1M worth of Feb 2027 $30 puts swept at the ask Institutions seem to be hedging for more downside even with that $150M financing news Looks like they’re not betting on a big reversal anytime soon

0 · Reply

NoRiskNoFun Aug. 10 at 2:28 PM

$UWMC $HTZ $TENX $SION $MPLT play coin toss game!

0 · Reply

NoRiskNoFun Aug. 10 at 12:27 PM

$MPLT $CVRX $TENX $SION $KPTI strong rebound!

0 · Reply

SHVR89 Aug. 7 at 6:10 PM

$MPLT longterm

0 · Reply

hawkmdend Aug. 3 at 2:06 PM

$MPLT PPS should be $8 or lower. Their next PR should be about their earnings release and business update.

1 · Reply

SHVR89 Aug. 3 at 1:18 AM

$MPLT I see an oportunity on this, last year bought $MLTX and $NTLA on a similar patern Look like swing or even position trade to me GLE Watch fillings tomorrow can be different

1 · Reply

MarkGoldw Aug. 1 at 4:12 PM

$MPLT buy much as you can. Short is very stupid at the level.

1 · Reply

hawkmdend Aug. 1 at 2:19 AM

$MPLT No, two of their drugs failed(compared to the standard of care).

0 · Reply

MapLight Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Aug 13, 2026, 9:10 AM EDT - 1 day ago

MapLight Therapeutics Announces $150 Million Private Placement Financing

Aug 13, 2026, 7:00 AM EDT - 1 day ago

MapLight Therapeutics Quarterly report: Q2 2026

Aug 13, 2026, 7:00 AM EDT - 1 day ago

MapLight Therapeutics Earnings release: Q2 2026

2026-08-10T13:25:25.000Z - 4 days ago

MapLight Therapeutics downgraded to Neutral from Buy at UBS

2026-08-10T10:31:05.000Z - 4 days ago

MapLight Therapeutics downgraded to Neutral from Buy at UBS

Aug 3, 2026, 2:22 AM EDT - 11 days ago

MPLT Investors Have Opportunity to Join MapLight Therapeutics, Inc. Fraud Investigation with SBS Law

2026-07-28T13:20:20.000Z - 17 days ago

MapLight Therapeutics price target lowered to $25 from $40 at Craig-Hallum

2026-07-28T11:20:29.000Z - 17 days ago

MapLight Therapeutics price target lowered to $24 from $43 at Canaccord

BMY

2026-07-28T10:56:58.000Z - 17 days ago

MapLight downgraded to Equal Weight from Overweight at Morgan Stanley

2026-07-28T10:06:17.000Z - 17 days ago

MapLight Therapeutics price target lowered to $26 from $45 at H.C. Wainwright

Jul 27, 2026, 8:30 AM EDT - 18 days ago

MapLight's schizophrenia drug fails once-daily test, shares plunge

Jul 27, 2026, 8:00 AM EDT - 18 days ago

MapLight Therapeutics Transcript: Study result

Jul 27, 2026, 8:00 AM EDT - 18 days ago

MapLight Therapeutics Slides: Study result

Jul 27, 2026, 8:00 AM EDT - 18 days ago

MapLight Therapeutics Press release: Study result

2026-07-27T11:16:05.000Z - 18 days ago

MapLight Therapeutics announces topline results from ZEPHYR trial

Jul 27, 2026, 7:00 AM EDT - 18 days ago

MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia

2026-07-24T10:50:28.000Z - 21 days ago

MapLight Therapeutics price target raised to $43 from $35 at Canaccord

2026-07-21T11:11:50.000Z - 24 days ago

MapLight Therapeutics price target raised to $52 from $48 at UBS

2026-07-20T20:45:08.000Z - 24 days ago

BMO starts MapLight at Outperform, eyes validation data in August

2026-07-20T20:30:21.000Z - 25 days ago

MapLight Therapeutics initiated with an Outperform at BMO Capital

2026-07-10T11:25:09.000Z - 5 weeks ago

MapLight Therapeutics price target raised to $45 from $42 at Needham

2026-06-24T20:30:17.000Z - 7 weeks ago

MapLight Therapeutics initiated with a Strong Buy at Raymond James

Jun 24, 2026, 7:00 AM EDT - 7 weeks ago

MapLight Therapeutics Announces Changes to Board of Directors

CNS

2026-06-23T16:56:05.000Z - 7 weeks ago

MapLight Therapeutics price target lowered to $40 from $43 at Craig-Hallum

Jun 22, 2026, 8:00 AM EDT - 7 weeks ago

MapLight Therapeutics Transcript: Study result

Jun 22, 2026, 8:00 AM EDT - 7 weeks ago

MapLight Therapeutics Press release: Study result

Jun 22, 2026, 8:00 AM EDT - 7 weeks ago

MapLight Therapeutics Slides: Study result

2026-06-22T11:34:25.000Z - 7 weeks ago

MapLight Therapeutics announces IRIS trial misses primary endpoint

Jun 22, 2026, 7:00 AM EDT - 7 weeks ago

MapLight Announces Topline Results from Phase 2 IRIS Study for ML-004 in Autism Spectrum Disorder

ASD

2026-06-02T10:41:14.000Z - 2 months ago

MapLight Therapeutics price target raised to $36 from $28 at Stifel

May 14, 2026, 4:05 PM EDT - 3 months ago

MapLight Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

May 14, 2026, 4:00 PM EDT - 3 months ago

MapLight Therapeutics Earnings release: Q1 2026

May 14, 2026, 4:00 PM EDT - 3 months ago

MapLight Therapeutics Quarterly report: Q1 2026

May 8, 2026, 7:00 AM EDT - 3 months ago

MapLight Therapeutics to Participate in Upcoming Investor Conferences

May 1, 2026, 7:00 AM EDT - 3 months ago

MapLight Therapeutics Announces Completion of Enrollment in ZEPHYR Phase 2 Trial and Updates Expected Timing of Topline Results

Apr 29, 2026, 8:00 AM EDT - 3 months ago

MapLight Therapeutics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 3 months ago

MapLight Therapeutics Proxy statement: Proxy filing

Mar 26, 2026, 7:00 AM EDT - 5 months ago

MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Mar 26, 2026, 7:00 AM EDT - 5 months ago

MapLight Therapeutics Annual report: Q4 2025

Mar 26, 2026, 7:00 AM EDT - 5 months ago

MapLight Therapeutics Earnings release: Q4 2025

Mar 26, 2026, 7:00 AM EDT - 5 months ago

MapLight Therapeutics Slides: Corporate presentation

Mar 18, 2026, 6:00 PM EDT - 5 months ago

MapLight Therapeutics Transcript: Stifel 2026 Virtual CNS Forum

Jan 9, 2026, 7:00 AM EST - 7 months ago

MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026

Jan 9, 2026, 7:00 AM EST - 7 months ago

MapLight Therapeutics Slides: Corporate Presentation

Jan 5, 2026, 7:00 AM EST - 7 months ago

MapLight Therapeutics Receives Fast Track Designation for ML-007C-MA for Alzheimer's Disease Psychosis

Dec 16, 2025, 7:00 AM EST - 8 months ago

SandboxAQ and MapLight Therapeutics Announce Strategic Collaboration to Discover and Develop Novel CNS Therapies

Dec 4, 2025, 7:00 AM EST - 9 months ago

MapLight Therapeutics Reports Third Quarter Financial Results and Highlights Corporate Progress

Dec 4, 2025, 7:00 AM EST - 9 months ago

MapLight Therapeutics Quarterly report: Q3 2025

Dec 4, 2025, 7:00 AM EST - 9 months ago

MapLight Therapeutics Earnings release: Q3 2025

Dec 4, 2025, 7:00 AM EST - 9 months ago

MapLight Therapeutics Slides: Corporate Presentation

Oct 29, 2025, 9:06 AM EDT - 10 months ago

MapLight Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Oct 27, 2025, 11:48 AM EDT - 10 months ago

MapLight Therapeutics valued at $787 million as shares jump in Nasdaq debut

Oct 26, 2025, 5:30 PM EDT - 10 months ago

MapLight Therapeutics Announces Pricing of Initial Public Offering

Oct 6, 2025, 2:00 AM EDT - 11 months ago

MapLight Therapeutics Registration statement: Registration Filing

Sep 19, 2025, 4:11 PM EDT - 11 months ago

MapLight Therapeutics IPO Registration Document (S-1)

Sep 19, 2025, 7:00 AM EDT - 11 months ago

MapLight Therapeutics Registration statement: Registration Filing

Sep 19, 2025, 6:15 AM EDT - 11 months ago

CNS disorder biotech MapLight Therapeutics files for a $100 million IPO

prismmarketview Aug. 14 at 1:37 PM

0 · Reply

Biotech_Pharma_Investor Aug. 14 at 8:59 AM

$MPLT my summary assessment for anyone interested https://substack.com/profile/160232761-biotech-pharma-investor/note/c-314520519?r=2nece1

0 · Reply

QuantInsider Aug. 13 at 8:58 PM

0 · Reply

NoRiskNoFun Aug. 10 at 2:28 PM

$UWMC $HTZ $TENX $SION $MPLT play coin toss game!

0 · Reply

NoRiskNoFun Aug. 10 at 12:27 PM

$MPLT $CVRX $TENX $SION $KPTI strong rebound!

0 · Reply

SHVR89 Aug. 7 at 6:10 PM

$MPLT longterm

0 · Reply

hawkmdend Aug. 3 at 2:06 PM

$MPLT PPS should be $8 or lower. Their next PR should be about their earnings release and business update.

1 · Reply

SHVR89 Aug. 3 at 1:18 AM

$MPLT I see an oportunity on this, last year bought $MLTX and $NTLA on a similar patern Look like swing or even position trade to me GLE Watch fillings tomorrow can be different

1 · Reply

MarkGoldw Aug. 1 at 4:12 PM

$MPLT buy much as you can. Short is very stupid at the level.

1 · Reply

hawkmdend Aug. 1 at 2:19 AM

$MPLT No, two of their drugs failed(compared to the standard of care).

0 · Reply

WVU1 Jul. 31 at 7:21 PM

$MPLT Great buying opportunity.

0 · Reply

LittleBagBob Jul. 31 at 2:10 PM

$MPLT @Pika_Capital what is your take? If you don’t mind.

1 · Reply

MesserschmittBavaria Jul. 31 at 6:19 AM

$MPLT pay attention before other news I’ll wait for my investment

0 · Reply

TraderjoeBB Jul. 31 at 2:26 AM

$MPLT bullish news expecting a run up tomorrow

0 · Reply

Zardiw Jul. 30 at 11:19 PM

$DFNS: Flagged Early by #DDAmanda. Chart: Similar early alerts: $MPLT $MSS $VRRM Best Stock Screener: https://DDAmanda.com

0 · Reply

hawkmdend Jul. 30 at 9:18 PM

$MPLT Here is a brief AI summary of what happened to them with the most advanced drugs in their pipeline. All I'm saying is that after what happened, their current valuation is too high, and their roadmap for approval is now more complicated and much more expensive. They should be valued at cash on hand or less, and nothing more, because their drugs are not better than the standard of care (the FDA is not going to approve something subpar).

0 · Reply

hawkmdend Jul. 30 at 7:37 PM

$MPLT You can play with the data to justify their valuation, but two of their drugs failed( are no better than the standard of care). I'm saving this post, and we can have the conversation again when the PPS is under $8. Btw… review their latest SEC filings; they are burning over $50M. In two weeks, they will have to report earnings or the lack of), and you will see more cash burned probably $50M++ again). Why?!? Simple: with two drugs failing, they have to push the rest of the pipeline…

1 · Reply

MesserschmittBavaria Jul. 30 at 7:30 PM

$MPLT Morgan Stanley instead downgraded MapLight Therapeutics to Equalweight from Overweight, lowering the price target to $21 from $34 due to the results on pharmacological activity that emerged from the study Just my opinion ..it will re-gotcha 10$

0 · Reply

Prof_Shadowknight Jul. 30 at 7:29 PM

$MPLT I’m not selling diamond hands

0 · Reply

LittleBagBob Jul. 30 at 7:20 PM

$MPLT @hawkmdend Yet another used car salesman bear. that greedy? Of course you are. Verifiable facts pulled from the SEC filings: 1. Their Phase two did NOT fail. The twice daily met its primary endpoint and was a success. The once daily did not hit statistical significance metrics which led to the rapid price drop. Not a failure, a bump in the road but the car is still heading straight. 2. They have a significant cash runway that should get them well into 2027 without diluting. They were burning $9-$12M/month in the midst of the phase 2. 3. The next big catalyst will be their meeting with the FDA in which it will be decided with they will move to the phase 3 with their twice daily or pursue (not what stock holders want) a different variant of their once a day. They also have other drugs in or close to being in Phase 2. It’s high risk like any smaller Biostock but don’t listen to people just throwing out numbers, do your DD, and hopefully we will come out green.

0 · Reply

hawkmdend Jul. 30 at 5:55 PM

$MPLT Back in June, their other drug failed. Now the main one too. They are burning over $50M per quarter. No partnership or collaboration on the horizon. Based on future cash balance, PPS under $8 looks appropriate.

0 · Reply

EvCe Jul. 30 at 2:12 PM

$MPLT adding

0 · Reply

Market Cap	484.99M
Revenue (ttm)	0.00
Net Income (ttm)	-161.15M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	451,403
Avg Vol	902,094
Day's Range	N/A - N/A
Shares Out	42.62M
Stochastic %K	26%
Beta	N/A
Analysts	Strong Sell
Price Target	$29.92